Wyoming Pharmacy and Therapeutics (P&T) Committee
Public Comment Policy
(Effective 2/1/10; updated 11/20/12)

• A public comment period is provided during all P&T Committee meetings. Each presenter will have a maximum of three minutes to present all oral comments to the Committee.

• Any handouts/written information for the Committee should be provided electronically to:
  alewis13@uwyo.edu AND lgm@uwyo.edu

at least ten business days (14 calendar days) prior to a meeting. This review time will allow the Committee to more fully incorporate the information into any recommendations or decisions made during the meeting.

Any written information not submitted as above will not be submitted to the Committee for consideration. Handouts may not be provided at the meeting. Studies which were not provided in time for Committee consideration may not be referred to in public comment.

• Due to time constraints associated with decreasing the number of meetings held each year, presenters are asked not to present information that is readily available in the package insert or is well-known to most health care providers.

• Presenters will be asked to answer the following questions during their presentation:

  1. What action are you asking the Committee to take?
  2. What evidence do you have to support the requested action? (ie comparative studies if you are asking for your product to be preferred with or over another agent).
  3. What evidence is there that is contrary to the requested action? (ie any negative studies conducted with your product).
  4. If requesting access for a particular medication, what makes this medication different from others available to treat the same condition?

All questions on page 2 must be answered. You can use the form on page 2 or copy the questions to another document. This information must be submitted following the above policy for written information at least ten business days prior to the meeting. Presenters are strongly encouraged to provide published evidence to support the comments that will be made during the meeting as the Committee values this type of information. All evidence must be submitted electronically per the policy above.
WY P & T Committee Public Comment Request Form

Name

Affiliation

(If you are employed by a pharmaceutical manufacturer, you may stop here)

Which person or organization alerted you to this meeting?

Are you being offered financial or other incentives to attend this meeting (e.g., money, the offer of dinner, free samples in the clinic, patient referrals, gifts)?

Were you asked to speak about something specifically?

Have you been a paid speaker for any pharmaceutical manufacturer? Which manufacturer?

Do you own stock in the company mentioned above?

Have you received funding for research by a pharmaceutical manufacturer?

Do you often prescribe this medication or medications in this therapeutic class?

Presentation information:

What action are you asking the Committee to take?

What evidence do you have to support the requested action? (ie comparative studies if you are asking for your product to be preferred with or over another agent).

What evidence is there that is contrary to the requested action? (ie any negative studies conducted with your product).

If requesting access for a particular medication, what makes this medication different from others available to treat the same condition?

Please attach all studies cited above.

By signing this form, I hereby attest that the answers given above are true, correct, complete, and not intended to mislead

Signature and Date
Policy for Contacting P&T Committee Members

All contact from PhRMA representatives regarding matters directly related to the P&T Committee should be made through the DUR program at the University of Wyoming School of Pharmacy. Provision of written materials or opportunity for live presentation to the Committee may be requested by contacting Aimee Lewis, DUR Manager, at alewis13@uwyo.edu, or Laura Miller, Program Assistant, at lgm@uwyo.edu or by calling 307-766-6750. If Committee members are approached concerning a specific Committee issue, they may refer the representative to the DUR program. This policy is being made in order to ensure that all Committee members are provided the same information for use in decision-making. In addition, because proceedings of the P&T Committee are public, all information provided should be made available in a public forum instead of private, one-on-one conversations.